ANN ARBOR, Mich., – April 22, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial. Kraig Labs has successfully produced cocoon at rates that exceeded all expectations and control parameters for these trials.

Under the supervision and guidance of a top independent sericulture expert, Dr. Nirmal Kumar, whom the Company brought in to oversee these trials, Kraig Labs has now finished the critical rearing stage for both parental strains of the BAM-1 hybrid. Each parental strain was divided into two batches, creating a total of four separate production trial groups. The result was an absolute success, with all four production batches achieving excellent growth rates and nearly perfect cocooning.

“I am very impressed with the robustness of the BAM-1 parental lines,” said Dr. Nirmal Kumar. “The colony has exhibited perfect health and grown very quickly. The team’s rearing skills are rapidly advancing, and they are ready to increase production. Based on what I have observed from rearing this first generation, I expect that the Company will have a very successful production scale-up.”

The launch of these operations, after careful preparation and under the supervision of a renowned sericultural expert, demonstrated that the BAM-1 parental lines meet the performance and robustness necessary for large-scale production. With the successful completion of cocooning, the Company can confirm that the BAM-1 line has proven it is ready for scale-up. Over the next two weeks the Company will collect the moths from these cocoons to breed the next generation of production hybrid silkworms and conclude the critical parental line trial.

Meticulous testing and screening of the silkworms throughout the entire rearing cycle proved that the BAM-1 lines are the strongest, most robust recombinant spider silk strains the Company has ever produced. With zero observation of disease within any of the four production batches, the Company and its consultants are now prepared to accelerate the drive to reach metric-ton-level production.

“The BAM-1 hybrids have exceeded our expectations thanks in part to our team, our outside consultants, and Dr. Nirmal Kumar’s guidance,” said Company founder and CEO, Kim Thompson. “Initial results have shown faster growth rates, nearly perfect cocooning rates, and larger cocoon size than we have seen even in our own R&D center. We are in an entirely new ball game now. 

The current production trial will continue to run for two or three weeks. Additional data on each of the four production batches is being collected and processed. “We are 85% to 90% through the trial of the parental strains, and every single batch of our new strains sailed through what we expected to be the toughest challenges,” continued Thompson. “Even in advance of the conclusion of the trials, I am happy to report that our two-year program of acclimation to the production environment appears to have been achieved.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 15, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that the spring production trials for the new BAM-1 hybrid have begun and are well on track to meet the Company’s expectations and timeline.

The Company successfully launched the production trials of BAM-1, its newest and most robust recombinant spider silk production silkworm hybrid, on time and in line with its production roadmap. The Company’s CEO remains in Asia to directly oversee the production trial of the BAM-1 parental strains and monitor their performance.

Following health screenings and daily monitoring of the colony, the Company can now report that this is currently the strongest and healthiest batch of silkworms it has ever produced in Southeast Asia. Specifically, disease screening by the Company and its consultants has shown zero instances of disease in the colony. This can be attributed in part to the improved genetics and robustness of the BAM-1 parental strains. Moreover, significant credit for this improved performance must also be attributed to the knowledge and rearing technology transfer that Dr. Nirmal Kumar, of India, has brought to the team.

“Our team invested heavily in improving the robustness of our production recombinant spider silk strains based on hard lessons learned and the testing data collected in 2023. With the support and added insight Dr. Nirmal Kumar is providing, we are on track for the most productive and successful spider silk production year in the Company’s history,” said founder and CEO, Kim Thompson. “Dr. Nirmal Kumar will be on the ground working with our team through this entire trial of the parental strains in order to lay a solid foundation for all future production. I believe we are in the midst of a breakout year for the Company as we continue to hit our marks on the business plan and deliver on our vision for commercial scale spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 8, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has signed a landmark agreement with the Vietnam Sericulture Association (“VSA”). As part of this agreement, the Company disclosed its production plans and schedule for the next twenty-four months to the VSA to obtain cooperation in reaching its production targets. This agreement establishes a collaborative working effort between the Company and the VSA, something the Company has been actively working towards for some time.

Under the terms of the agreement, in addition to support and advice on production logistics, the VSA has agreed to assist the Company in obtaining formal intellectual property registration of its BAM-1 hybrid silkworm strain in Vietnam. 

This definitive agreement strengthens the collaboration between the Company and the VSA, building on and expanding the Memorandum of Understanding announced on January 30, 2024. This landmark agreement establishes the framework and much of the logistical support needed for the Company to achieve metric-ton levels of production. 

“This agreement is the culmination of many years of work with various governmental and non-governmental agencies to demonstrate our technology and its potential,” said Company founder and CEO, Kim K. Thompson. “This new relationship with the VSA underlines our commitment to South East Asia and, we believe, significantly strengthens our position as we scale up production. With this agreement finalized, we are now working jointly with a capable partner to see that vision fulfilled.”

“We have been following developments at Kraig Labs for many years and are very happy now to be working directly with them,” said Dr. Le Quang Tu, President of the Vietnamese Sericulture Association. “We believe that Kraig’s technology will have a significant positive impact on our industry. They have applied a thoughtful, step-by-step approach. Now, we will take a step together.”

The Company’s CEO remains in Vietnam, overseeing operations directly. Kraig Labs anticipates that Thompson will provide additional announcements and updates regarding the Company’s accelerating progress over the coming weeks. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 28, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute (“RPI”).

Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics.

This project used a new strain of Pseudomonas bacteria capable of converting depolymerized polyethylene into targeted recombinant proteins. While this work is in the early stages, it shows the potential for this process to create spider silk-like proteins from partially decomposed plastics.

Plastic wastes continue to accumulate globally, resulting in disposal and recycling challenges as well as increased levels of microplastics showing up in our food and water supplies. Creating useful and easily biodegradable silk proteins from these materials could help alleviate this growing concern.

“I am encouraged to see the continued focus and breadth of research developing in the field of spider silk technologies,” said CEO and Founder, Kim Thompson. “While this approach using bacteria doesn’t directly create silk fibers, the potential impact of creating technologies to address the growing plastic waste and convert that into useful and biodegradable materials is very exciting. We congratulate the team at Rensselaer Polytechnic Institute for their work. While our production methods have no direct connection to the work at RPI, the commonality is environmentally friendly spider silk through molecular biology.”

Kraig Labs’ recombinant spider silk production model utilizes traditional silk production systems involving planting mulberry trees to harvest and feed the leaves to silkworms. The Company’s specialized silkworms have been scientifically enhanced through molecular biology to create recombinant spider silk cocoons that are reeled to produce spider silk yarns and fabrics. Kraig Labs is currently working to expand its spider silk production footprint. The Company’s CEO and its leading sericulture expert are currently in Southeast Asia working to prepare for the launch of the Company’s spring 2024 production trials and the 2024 silk production season.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 19, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces today that Dr. Nirmal Kumar, a globally recognized expert in sericulture, will join the Company’s Senior Management in Vietnam to supervise the start of the spring production trials and the launch of the BAM-1 hybrid. 

Dr. Nirmal Kumar gained recognition as a leading authority in the breeding and rearing of silkworms through his 37 years of work at the Central Sericulture Research & Training Institute (“CSRTI”) in India. He specializes in research, training, and testing of silkworm breeds, mulberry cultivation, and rearing technologies. Dr. Nirmal Kumar joined the Kraig Labs team as a senior consultant in November of 2023, bringing world-class expertise in silkworm breeding and commercial scale rearing to the Company. 

Dr. Nirmal Kumar will join senior management to oversee operations and kick off the 2024 production season. He is tasked with reviewing the Company’s production operations and that of its third party contract manufacturers. He will provide guidance and training to the team and oversee the rearing of the first generation of BAM-1 parent lines. He will also assist senior management in outlining the blueprints for the planned continued expansion of production capacity in Vietnam.

“Dr. Nirmal Kumar brings a wealth of firsthand knowledge and expertise. We are very excited to have him working side by side with our team as we mark this pivotal milestone for the commercialization of recombinant spider silk,” said Founder and CEO of Kraig Labs, Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 12, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces today that senior management members will travel to Vietnam this week to oversee the launch of the spring production trials and lay the groundwork for the Company’s planned commercial expansion.

The launch of the BAM-1 production trial is the next critical benchmark in the Company’s plan for commercial-scale production of recombinant spider silk. Management will closely monitor all aspects of the spring trials, which are seen as the probable blueprint for large-scale production of spider silk.

In addition to overseeing the spring production trials, senior management plans to lay the groundwork for further production growth, scouting and identifying down-market production partners, and finalizing agreements with private and governmental entities.

“We are excited to be on the verge of launching our much-anticipated spring production trials. Just as critically, we’re eager to finalize our agreements with various entities that we believe will be instrumental in Kraig Labs’ growth,” said Founder and CEO, Kim Thompson. “I look forward to joining our Vietnamese team as we launch production trials and gather critical data on the performance of our BAM-1 hybrid and its parent strains under real field conditions.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 6, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces today that it is preparing a second business investment application in Vietnam as part of the planned expansion of its business operations. The Company expects to submit this second investment license application this month. 

This new license will be utilized in connection with the Company’s recently announced memorandum of understanding with the Lam Dong Agro-Forestry Research and Experiment Center (“LAREC”) and the Vietnam Sericulture Association (“VSA”). This collaboration is designed to advance sericulture in Vietnam by leveraging the Company’s proprietary silk technology and expertise from the LAREC and VSA. 

The Investment License application is part of the creation of a new wholly-owned subsidiary of Kraig Labs, to be named Prodigy Silk. Prodigy Silk will be headquartered in the Company’s recently announced facility in Lam Dong Province. The Company expects this facility to serve as the operational center for its spring production trials. Renovations of this facility are currently underway, and the Company expects it to be fully operational in time for the spring trials.

“This business investment in the highlands has been a long-term strategic goal for Kraig Labs,” said Founder and CEO, Kim Thompson. “Over the last two quarters, we have consistently hit our marks and checked the boxes on our business plan. Each milestone we hit prepares the way for the next milestone.”

The Company’s management intends to remain aggressive in the execution of its business plan for the production of recombinant spider silk in 2024.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 27, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces that it has achieved homozygosity for the spider silk gene in both of the parental strains for its new production hybrid. Establishing homozygosity for the targeted gene in both parental strains means that the Company’s new BAM 1 hybrid production system is optimized for recombinant spider silk production.

The BAM 1 hybrid represents the Company’s latest innovation in the commercialization of recombinant spider silk technology. Achieving homozygosity for both BAM 1 parental strains is another significant milestone in the commercialization of recombinant spider silk. The reason homozygosity is important is because it results in higher levels of spider silk protein expression.

“Our team set an aggressive deadline for achieving homozygosity in the BAM 1 hybrid ahead of our spring production trials,” said CEO and Founder, Kim Thompson. “Today, I am pleased to report they met that goal and that BAM 1 hybrids, which will be our primary production strain for the upcoming production season, is now optimized for recombinant spider silk expression. Our team continues to hit its marks, and I am looking forward to a very exciting year for Kraig Labs and the commercial launch of our revolutionary spider silk technology.” 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 20, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces the creation of its first premium yarn combining its recombinant spider silk with Pima Cotton. This new yarn exemplifies the Company’s business model at work, capturing additional value-added vertical integration in the textile and garment markets.

This yarn was designed to blend the finest quality cotton with our remarkable spider silk to create a 100% natural fiber composite yarn for use in fabrics and finished garments. It was manufactured in collaboration with one of the world’s leading spinners of high-quality cotton yarns and fabrics. 

Working with its textile consultant, Jeff Dorton, the Company investigated several potential spinners before making a final selection. The decision was ultimately driven by the technical capabilities and production capacity of the spinner.

“This is just the first of many new materials we have planned that incorporate our revolutionary spider silk,” said CEO and Founder, Kim Thompson. “It seemed only fitting that our first composite yarns be blended with Pima Cotton, a luxurious natural fiber that compliments the natural elegance of our recombinant spider silk. With our spring production trials quickly approaching, identifying these first end markets and applications for commercial volumes of silk is a key focus of our team.”

The Company developed its first cotton-spider silk blend to target markets such as luxury dress wear and apparel. Kraig Labs is working to establish additional spider silk and natural fiber blends to address additional subsegments in formal wear. While these blends are targeted for luxury and fashion wear, the Company remains focused on its development of technical applications for its spider silk materials in defensive textiles, composites, and performance apparel.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 13, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces it has now taken possession of its new recombinant spider silk production center in Lam Dong Province, Vietnam. This new facility is located in the heart of Vietnam’s booming silk economy and will serve as the center of operations for the Company’s growing spider silk production in 2024.

The Company selected this facility and is opening this new operations center to support the significant expansion of silk production scheduled for spring 2024. 

Securing this new facility is happening in parallel with the Company’s recently announced MOU with the Vietnam Sericulture Association (“VSA”) and Lam Dong Agro-Forestry Research and Experiment Center (“LAREC”). 

Kraig Labs expects this center will serve as a central location for collaboration with the VSA and LAREC to enhance sericulture in Vietnam. The Company anticipates this facility will also serve as the distribution and collection hub for the resulting recombinant spider silk fibers, yarns, and fabrics. 

The facility is located in the center of Vietnam’s largest silk-producing region, providing excellent access to fresh mulberry, skilled sericulture staffing, and cocoon reeling facilities.

“We are prepared for 2024 to be a breakthrough year for the commercialization of spider silk. Positioning our operations in the heart of Vietnam’s silk manufacturing center is a significant element of that growth,” said CEO and Founder, Kim Thompson. “Our team is now preparing for the spring production trials and the launch of our new BAM 1 hybrid. We expect to have this new facility online to support these exciting milestones and the commercialization of our cost-effective, eco-friendly spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com